Volume 66, Issue 2, Pages (August 2014)

Slides:

Advertisements

Similar presentations

Volume 60, Issue 4, Pages (October 2011)

Advertisements

Volume 58, Issue 3, Pages (September 2010)

Volume 67, Issue 1, Pages (January 2015)

Volume 58, Issue 2, Pages (August 2010)

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

Volume 47, Issue 4, Pages (April 2005)

Volume 68, Issue 6, Pages e129-e131 (December 2015)

Volume 70, Issue 6, Pages (December 2016)

Volume 60, Issue 2, Pages (August 2011)

Volume 51, Issue 1, Pages (January 2007)

Volume 52, Issue 3, Pages (September 2007)

European Urology Oncology

Volume 74, Issue 2, Pages (August 2018)

The Role of Residual Tumor Resection in Patients with Metastatic Renal Cell Carcinoma and Partial Remission following Immunochemotherapy Olaf A. Brinkmann,

Volume 52, Issue 2, Pages (August 2007)

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Volume 68, Issue 1, Pages (July 2015)

Volume 67, Issue 1, Pages (January 2015)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Volume 52, Issue 4, Pages (October 2007)

Volume 72, Issue 5, Pages (November 2017)

Volume 59, Issue 2, Pages (February 2011)

Volume 63, Issue 1, Pages (January 2013)

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 65, Issue 1, Pages (January 2014)

Volume 71, Issue 1, Pages 1-3 (January 2017)

Volume 68, Issue 1, Pages 5-7 (July 2015)

Volume 71, Issue 3, Pages (March 2017)

Volume 53, Issue 4, Pages (April 2008)

Volume 70, Issue 5, Pages (November 2016)

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Volume 60, Issue 5, Pages (November 2011)

Laurent Boccon-Gibod European Urology Supplements

Volume 65, Issue 6, Pages (June 2014)

Volume 53, Issue 2, Pages (February 2008)

Volume 64, Issue 4, Pages (October 2013)

Volume 74, Issue 3, Pages (September 2018)

Volume 53, Issue 6, Pages (June 2008)

Volume 66, Issue 5, Pages (November 2014)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 2, Pages (August 2018)

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Tyrosine Kinase Inhibitors in Clinical Practice: Patient Selection

Volume 50, Issue 5, Pages (November 2006)

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

Volume 55, Issue 6, Pages (June 2009)

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Volume 53, Issue 1, Pages (January 2008)

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Kidney Cancer: Highlights from 2006

Resection of Intraabdominal Tumors With Cavoatrial Extension Using Deep Hypothermic Circulatory Arrest Christopher Lau, MD, Padraic O’Malley, MD, Mario.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Prognostic Impact of Comorbidity in Patients with Bladder Cancer

Sergio Bracarda European Urology Supplements

Volume 64, Issue 1, Pages (July 2003)

Volume 68, Issue 5, Pages (November 2015)

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Volume 52, Issue 1, Pages (July 2007)

Volume 67, Issue 4, Pages (April 2015)

Jan Roigas European Urology Supplements

European Urology Oncology

Volume 51, Issue 5, Pages (May 2007)

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Presentation transcript:

Volume 66, Issue 2, Pages 275-281 (August 2014) Temsirolimus in Daily Use: Results of a Prospective Multicentre Noninterventional Study of Patients with Metastatic Kidney Cancer Andres Jan Schrader, Sandra Seseke, Christian Keil, Edwin Herrmann, Peter J. Goebell, Steffen Weikert, Sandra Steffens, Lothar Bergmann, Jan Roigas, Thomas Steiner European Urology Volume 66, Issue 2, Pages 275-281 (August 2014) DOI: 10.1016/j.eururo.2013.08.055 Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 1 (a) Progression-free survival (PFS) and (b) overall survival (OS) for 386 evaluable patients receiving temsirolimus during the STARTOR trial plotted against the line of treatment (Kaplan-Meier). Neither the median PFS (5.3 vs 4.5 mo; p=0.27, log rank) nor the OS (10.5 vs 13.7 mo; p=0.62, log rank) differed significantly between patients without (n=162) and with (n=224) prior systemic therapy. European Urology 2014 66, 275-281DOI: (10.1016/j.eururo.2013.08.055) Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 2 (a) Progression-free survival (PFS) and (b) overall survival (OS) for 386 evaluable patients receiving temsirolimus during the STARTOR trial plotted against the histologic renal cell carcinoma (RCC) subtype (Kaplan-Meier). Neither the median PFS (5.1 vs 4.2 mo; p=0.32, log rank) nor the OS (12.6 vs 11.0 mo; p=0.28, log rank) differed significantly between patients with clear cell RCC (ccRCC) (n=297) and non-ccRCC or undefined RCC (n=89). European Urology 2014 66, 275-281DOI: (10.1016/j.eururo.2013.08.055) Copyright © 2013 European Association of Urology Terms and Conditions

Fig. 3 (a) Progression-free survival (PFS) and (b) overall survival (OS) for 386 evaluable patients receiving temsirolimus during the STARTOR trial plotted against the patient's age (Kaplan-Meier). Neither the median PFS (4.5 vs 5.1 mo; p=0.17, log rank) nor the OS (10.5 vs 13.5 mo; p=0.45, log rank) differed significantly between patients <65 yr of age (n=149) and ≥65 yr of age (n=237). European Urology 2014 66, 275-281DOI: (10.1016/j.eururo.2013.08.055) Copyright © 2013 European Association of Urology Terms and Conditions